Zentalis Pharmaceuticals, Inc. Net Income Loss

• Zentalis Pharmaceuticals, Inc. showed an increase of +17.4% in Net Income Loss from 2024 to 2025.
• This data is from Zentalis Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Zentalis Pharmaceuticals, Inc.'s Net Income Loss has declined by 200.2%.
• Historical annual values: Fiscal year 2025: -$137.06 million | Fiscal year 2024: -$165.84 million | Fiscal year 2023: -$292.19 million | Fiscal year 2022: -$236.81 million | Fiscal year 2021: -$158.73 million | Fiscal year 2020: -$117.84 million | Fiscal year 2019: -$45.66 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026